Compare Invesco Solar ETF (TAN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs TG Therapeutics Inc — how do they compare? Invesco Solar ETF trades at $43.64 (market cap $894.08M), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 9.1× Invesco Solar ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 34 Days and TG Therapeutics Inc for 16 Days on average.
| TAN | TGTX | |
|---|---|---|
Market Cap | $894.08M | $8.16B |
Volume | 370,994 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $59.06 |
52-Week Low | $43.00 | $26.94 |
Typical Hold Time | 34 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $43.6, up 0.16% on the day, amid a bearish technical signal with moving averages and key indicators like ADX signaling sell conditions. The ETF faces headwinds from high borrowing costs impacting solar project financing, as noted in recent news. Financial ratios are unavailable, but the fund's high expense ratio of 0.7% and historical volatility are points of concern for investors.
Outlook remains cautious due to sector-specific risks like interest rate sensitivity and market saturation. Investment opportunities exist for those bullish on long-term solar adoption, but risks include policy uncertainty and cost pressures. Analyst sentiment is mixed, with some highlighting underperformance versus broader markets.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
